Evercore ISI Group Maintains Outperform on Travere Therapeutics, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
Evercore ISI Group analyst Liisa Bayko maintains an Outperform rating on Travere Therapeutics (NASDAQ:TVTX) and keeps the price target at $30.
September 19, 2023 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evercore ISI Group maintains an Outperform rating on Travere Therapeutics and keeps the price target at $30.
The news is directly about Travere Therapeutics. The maintained Outperform rating and price target by Evercore ISI Group indicates a positive outlook for the company, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100